Progenics, Wyeth plan to file NDA for opioid receptor antagonist

By Lisa Kerner

Erie, Pa., April 21 - Progenics Pharmaceuticals, Inc. and Wyeth announced their plan to submit by early 2007 a New Drug Application with the Food and Drug Administration for subcutaneous methylnaltrexone (MNTX) in a new room-temperature formulation.

MNTX, a peripheral opioid receptor antagonist, is designed to treat the side effects of opioids without interfering with pain relief.

The second of two pivotal phase 3 clinical studies using the prior formulation showed MNTX is active in treating opioid-induced constipation in patients with advanced illness, according to a company news release.

In addition to the subcutaneous formulation, Progenics and Wyeth Pharmaceuticals, a division of Wyeth, are developing an intravenous formulation of MNTX for post-operative bowel dysfunction and an oral form of MNTX for the treatment of opioid side effects.

Progenics is a biopharmaceutical company located in Tarrytown, NY

Wyeth is a pharmaceutical and health care products company based in a Madison, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.